 |
|
|
| |
Development of Second Generation RNA Interference Therapy for Hepatitis B Virus Infection
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Emily P. Thi1, Xin Ye1, Ammen P. Dhillon1, Nicholas M. Snead1, Andrew S. Kondratowicz1, Alice H. L. Li1, Luying Pei1, Kyle D. Cobarrubias1,Agnes Jarosz1, Joseph Wasney1, Andrea Cuconati2, Rene Rijnbrand2, Michael J. Sofia2, Amy C. H. Lee1
1 Arbutus Biopharma Corp, Burnaby, BC, Canada 2 Arbutus Biopharma Inc, Doylestown, PA, United States
|
| |
|
|
|
|
|
